JPY 463.0
(2.89%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 735.18 Million JPY | 10.29% |
2022 | 666.58 Million JPY | 33.31% |
2021 | 500.03 Million JPY | 13.86% |
2020 | 439.15 Million JPY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 211.06 Million JPY | -6.79% |
2024 Q1 | 236.16 Million JPY | 21.17% |
2023 Q4 | 194.89 Million JPY | 16.68% |
2023 FY | 735.18 Million JPY | 10.29% |
2023 Q3 | 167.04 Million JPY | -15.28% |
2023 Q2 | 197.18 Million JPY | 12.0% |
2023 Q1 | 176.05 Million JPY | -6.75% |
2022 FY | 666.58 Million JPY | 33.31% |
2022 Q4 | 188.8 Million JPY | 38.49% |
2022 Q3 | 136.33 Million JPY | 0.0% |
2021 FY | 500.03 Million JPY | 13.86% |
2020 FY | 439.15 Million JPY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 98.315% |
Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.972% |
Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 99.864% |
Shionogi & Co., Ltd. | 197.62 Billion JPY | 99.628% |
Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | 80.324% |
Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 98.88% |
Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 97.467% |
Eisai Co., Ltd. | 533.01 Billion JPY | 99.862% |
Morishita Jintan Co., Ltd. | 5.28 Billion JPY | 86.081% |
Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 98.883% |
Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 98.411% |
Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 93.636% |
Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 91.069% |
Tsumura & Co. | 48.8 Billion JPY | 98.493% |
Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 97.794% |
Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 96.237% |
Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 98.847% |
Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 94.192% |
Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 98.183% |
KYORIN Holdings, Inc. | 45.39 Billion JPY | 98.38% |
Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | 82.315% |
Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | 87.634% |
SymBio Pharmaceuticals Limited | 5.22 Billion JPY | 85.923% |
MedRx Co., Ltd | 959 Million JPY | 23.339% |
Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | 74.417% |
Solasia Pharma K.K. | 1.47 Billion JPY | 50.191% |
Modalis Therapeutics Corporation | 2.37 Billion JPY | 68.988% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 96.958% |
Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 97.925% |
Toho Holdings Co., Ltd. | 99.81 Billion JPY | 99.263% |
Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | 67.431% |